Scholz J, Bamberg H, Moser A
Department of Neurology, Medical University of Lübeck, Germany.
Neurochem Int. 1997 Dec;31(6):845-9. doi: 10.1016/s0197-0186(97)00028-4.
As a compound of structural analogy with MPTP, N-methyl-norsalsolinol (2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; 2-MDTIQ) was recently identified in the brain and cerebrospinal fluid of patients with Parkinson's disease. As 2-MDTIQ cannot pass the blood-brain barrier, endogenous formation is suggested. Previous studies of the dopamine metabolism in Parkinson's disease have demonstrated an increased dopamine turnover in the presence of 2-MDTIQ. In the present study, we investigated the effect of 2-MDTIQ on tyrosine hydroxylase [L-tyrosine, tetrahydropteridine, oxygen: oxidoreductase (3-hydroxylating). EC 1.14.16.2; TH] activity in vitro using homogenated tissue of the rat nucleus accumbens as enzyme source. Basal TH activity was 20.1 +/- 5.9 pmol L-3,4-dihydroxyphenylalanine (L-DOPA)/min/mg protein. 2-MDTIQ non-competitively inhibited basal TH activity with an IC50 of 10 microM. After addition of 0.1 mM 2-MDTIQ, enzyme activity was nearly completely blocked. These results indicate that the endogenous formation of 2-MDTIQ in consequence of an impaired dopamine metabolism may in turn lead to a decrease in dopamine synthesis. Thus, 2-MDTIQ is suggested not only to represent an endogenous marker of Parkinson's disease, but also to support changes in the transmitter synthesis of dopaminergic neurons. Since previous investigations have moreover demonstrated a cytotoxic potential of 2-MDTIQ, these findings require special attention. 2-MDTIQ may represent an essential factor in the degenerative process of Parkinson's disease.
作为一种与1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)结构类似的化合物,N-甲基去甲索尔索林醇(2-甲基-6,7-二羟基-1,2,3,4-四氢异喹啉;2-MDTIQ)最近在帕金森病患者的大脑和脑脊液中被发现。由于2-MDTIQ不能通过血脑屏障,提示其为内源性生成。先前关于帕金森病多巴胺代谢的研究表明,在存在2-MDTIQ的情况下多巴胺周转率增加。在本研究中,我们以大鼠伏隔核匀浆组织为酶源,体外研究了2-MDTIQ对酪氨酸羟化酶[L-酪氨酸、四氢生物蝶呤、氧气:氧化还原酶(3-羟化)。EC 1.14.16.2;TH]活性的影响。基础TH活性为20.1±5.9 pmol L-3,4-二羟基苯丙氨酸(L-DOPA)/分钟/毫克蛋白质。2-MDTIQ非竞争性抑制基础TH活性,IC50为10 μM。加入0.1 mM 2-MDTIQ后,酶活性几乎完全被阻断。这些结果表明,多巴胺代谢受损导致的2-MDTIQ内源性生成可能反过来导致多巴胺合成减少。因此,2-MDTIQ不仅被认为是帕金森病的内源性标志物,而且还支持多巴胺能神经元递质合成的变化。此外,由于先前的研究已经证明2-MDTIQ具有细胞毒性潜力,这些发现需要特别关注。2-MDTIQ可能是帕金森病退行性过程中的一个重要因素。